
Dan Lauria
Ask VT AI
View News Summary
- Gilead Sciences reports strong Q2 2025 results, driven by robust HIV drug sales, and raises full-year guidance, making its stock a top performer.
- Pirates' Paul Skenes sets MLB record with dominant shutout performance
- Under Armour's weak Q1 sales and tariff pressures lead to a plunge in its stock price.
20 hours

United States Politics
Discover the latest news, candidates, and key topics of US politics
Ask VT AI
View News Summary
- Gilead Sciences reports strong Q2 2025 results, driven by robust HIV drug sales, and raises full-year guidance, making its stock a top performer.
- Pirates' Paul Skenes sets MLB record with dominant shutout performance
- Under Armour's weak Q1 sales and tariff pressures lead to a plunge in its stock price.
20 hours

United States Politics
Discover the latest news, candidates, and key topics of US politics
Most Reported By
News from Dan Lauria
News from Dan Lauria